MAPT and Alzheimer disease: First, although strict MRI criteria, including the medial temporal lobe atrophy score, were included in participant recruitment, we did not detect Aβ and tau markers using CSF or PET to exclude patients with mixed AD pathology, which could aggravate cognitive impairment and neurodegeneration in patients with SIVD.